PURPOSE: To test a combination of dexamethasone intravitreal implant with macular grid laser formacular edema in patients with branch retinal vein occlusion (BRVO). DESIGN: Prospective interventional, randomized, multicenter study. METHODS: Patients with macular edema secondary to BRVO underwent an Ozurdex intravitreal implant at baseline. After 1 month, patients were randomly assigned to 2 study groups. Patients in Group 1 were followed up monthly and retreated with Ozurdex implant whenever there was a recurrence of macular edema or a decrease in best-corrected visual acuity (BCVA). In Group 2 patients macular grid laser was performed between weeks 6 and 8. After that, patients were followed up and retreated as for Group 1. RESULTS: In Group 1 at 4 months, mean BCVA was 0.49 ± 0.35 logMAR and central retinal thickness (CRT) was 391±172mm; both improved significantly at 6months, to 0.32 ± 0.29 logMAR and 322 ± 160mm, respectively. In Group 2, CRT was reduced significantly to 291 ± 76 mmat 4months, andBCVAimproved to0.25±0.20logMAR.At the final visit, BCVA was 0.18 ± 0.14 logMAR and mean CRT was 271 ± 44 mm. The number of Ozurdex implants at 4 months was 12 of 25 (48%) in Group 1 patients vs 3 of 25 (12%) inGroup 2 patients (P[.012). At 6months 3 of 25 patients (12%) in Group 1 vs 0 of 25 (0%) in Group 2 (P [ .23) were retreated. CONCLUSIONS: The combination of Ozurdex implant and macular grid laser is synergistic in increasing BCVA and lengthening the time between injections.

Combination therapy with dexamethasone intravitreal implant and macular grid laser in patients with branch retinal vein occlusion.

SPECCHIA, Claudia;
2014-01-01

Abstract

PURPOSE: To test a combination of dexamethasone intravitreal implant with macular grid laser formacular edema in patients with branch retinal vein occlusion (BRVO). DESIGN: Prospective interventional, randomized, multicenter study. METHODS: Patients with macular edema secondary to BRVO underwent an Ozurdex intravitreal implant at baseline. After 1 month, patients were randomly assigned to 2 study groups. Patients in Group 1 were followed up monthly and retreated with Ozurdex implant whenever there was a recurrence of macular edema or a decrease in best-corrected visual acuity (BCVA). In Group 2 patients macular grid laser was performed between weeks 6 and 8. After that, patients were followed up and retreated as for Group 1. RESULTS: In Group 1 at 4 months, mean BCVA was 0.49 ± 0.35 logMAR and central retinal thickness (CRT) was 391±172mm; both improved significantly at 6months, to 0.32 ± 0.29 logMAR and 322 ± 160mm, respectively. In Group 2, CRT was reduced significantly to 291 ± 76 mmat 4months, andBCVAimproved to0.25±0.20logMAR.At the final visit, BCVA was 0.18 ± 0.14 logMAR and mean CRT was 271 ± 44 mm. The number of Ozurdex implants at 4 months was 12 of 25 (48%) in Group 1 patients vs 3 of 25 (12%) inGroup 2 patients (P[.012). At 6months 3 of 25 patients (12%) in Group 1 vs 0 of 25 (0%) in Group 2 (P [ .23) were retreated. CONCLUSIONS: The combination of Ozurdex implant and macular grid laser is synergistic in increasing BCVA and lengthening the time between injections.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11379/327306
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 14
social impact